Categories
Change Password!
Reset Password!
Remote electrical neuromodulation device is an effective, stable, and safe option for acute migraine relief, serving as both a standalone alternative to pharmaceuticals and an adjunct to medications.
A new analysis of data from over 12,000 migraine sufferers across the U.S. highlighted the effectiveness and safety of remote electrical neuromodulation (REN) as an acute treatment for migraine. The FDA-cleared device, Nerivio®, was used either alone or with medication, and demonstrated substantial real-world benefits.
The goal was to offer an extensive assessment of the efficiency, safety, drug-device interactions, and dose stability of REN wearable device across a large real-world dataset for migraine management.
This device featured a migraine diary for patients to record symptoms prior to and 2 hours after treatment. Real-world data from U.S. patients using the device (October 2019–May 2021) were analyzed to assess: (a) REN usage patterns as standalone or combination therapy, (b) individual efficiency across treatments, (c) treatment intensity distribution (electroceutical dose), and (d) adverse event prevalence and severity.
Findings:
This analysis underscores REN's potential as a reliable standalone or adjunct therapy, revolutionizing migraine management without the need for pharmaceuticals.
Frontiers in Pain Research
Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine
Jessica Ailani et al.
Comments (0)